Pune: CSIR-National Chemical Laboratory (CSIR-NCL), Pune, recently licensed the technology for producing bacterial nanocellulose for wound care and cosmetics applications to Rapidcure Healthcare Pvt. Ltd.
‘The CSIR-NCL technology uses a high-yield fermentative process for the production of high-value bacterial nanocellulose films from low-cost carbon sources. Syed Dastager’s team at CSIR-NCL developed this technology and validated it at a lab scale. The nanocellulose produced has very high purity levels and unique micromorphology enabling it to use for various commercially important applications. Bacterial nanocellulose is a unique material that offers a range of benefits, including high tensile strength, biodegradability, and biocompatibility,’ said the official press release from NCL.
In his statement to the media, Ashish Lele, Director of CSIR-NCL said, “We are excited to see our research on bacterial nanocellulose technology being adopted by Rapidcure Healthcare for commercialization. We believe this technology has the potential to yield new products in various market segments, including for wound care and cosmetics applications. We look forward to working with our partners in taking this technology from the lab scale to commercialization, and the benefits it would bring to society.”
‘The CSIR-NCL technology uses a high-yield fermentative process for the production of high-value bacterial nanocellulose films from low-cost carbon sources. Syed Dastager’s team at CSIR-NCL developed this technology and validated it at a lab scale. The nanocellulose produced has very high purity levels and unique micromorphology enabling it to use for various commercially important applications. Bacterial nanocellulose is a unique material that offers a range of benefits, including high tensile strength, biodegradability, and biocompatibility,’ said the official press release from NCL.
In his statement to the media, Ashish Lele, Director of CSIR-NCL said, “We are excited to see our research on bacterial nanocellulose technology being adopted by Rapidcure Healthcare for commercialization. We believe this technology has the potential to yield new products in various market segments, including for wound care and cosmetics applications. We look forward to working with our partners in taking this technology from the lab scale to commercialization, and the benefits it would bring to society.”